IMMUNEONCO-B (01541) continued its upward momentum with another surge exceeding 9%. As of press time, the stock was trading 7.94% higher at HK$15.77, with a turnover of HK$21.83 million.

On the news front, IMMUNEONCO recently announced that it has submitted an application to the Center for Drug Evaluation of the National Medical Products Administration for a Phase III clinical trial of IMM2510 for the treatment of immune therapy-resistant non-small cell lung cancer (NSCLC). The company has also recently submitted two additional Phase III registration clinical trials targeting different types of lung cancer.

The company reported that Phase I study data presented at the 2025 World Lung Cancer Conference demonstrated promising results. Among 17 evaluable patients with advanced squamous non-small cell lung cancer (SQ-NSCLC) who had previously received immunotherapy, IMM2510 achieved an objective response rate of 35.3% and a disease control rate of 76.5%. The median duration of response was 7.59 months, with a median progression-free survival of 9.4 months.

Based on these encouraging results, the company plans to further validate the efficacy and safety of IMM2510 through Phase III clinical trials, aiming to provide more effective treatment options for lung cancer patients.